ARISTOCORT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1959 for systemic and local anti-inflammatory treatment. The drug is administered via injection and is used across multiple inflammatory and autoimmune indications. Specific therapeutic uses are not detailed in available data, but the injection route suggests intra-articular, intralesional, or systemic administration.
LOE Approaching
Legacy product nearing loss of exclusivity with moderate competitive pressure (30), likely supporting a smaller, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Currently zero linked job openings reflect the product's mature, legacy status under Fosun Pharma ownership. Roles in ARISTOCORT tend to focus on maintaining market share and managing physician relationships rather than driving growth or innovation.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.